The CHIPS R&D Office's Always-Open Door Closes Monday. It Will Not Reopen Until November.

A rolling broad agency announcement is supposed to be the one federal instrument without a deadline. You submit when the science is ready, not when the calendar says so. That is the entire value proposition of the CHIPS R&D Office's BAA, 2025-NIST-CHIPS-CRDO-01, which accepts applications on a continuous basis through September 30, 2029.

On September 15, 2026, that door closes. NIST has announced that collection of applications under the CRDO BAA "will be temporarily paused" for system upgrades. During the pause, no white papers, no pre-negotiation packages, and no investment fund applications may be submitted — including submissions responding to invitations CRDO has already issued. The office expects to reopen the portal in November 2026.

Anything submitted before Monday gets reviewed under the BAA as normal. Anything not submitted by Monday waits roughly eight weeks. For a program with a $10 million minimum funding request and a two-path structure where the first step determines everything downstream, eight weeks is not a rounding error.

What is actually being paused

The CRDO BAA is the successor instrument to a program that has been restructured more than once. In April 2026, CHIPS R&D amended the BAA to split it into two distinct pathways, and the amendment changed who decides which one you are on.

The R&D Project Path is the conventional route: research, prototyping, and technology development, funded through a cooperative agreement or similar instrument.

The Investment Fund Path is the newer and stranger one. Rather than funding a defined project, CRDO makes what the amendment calls "investment style awards" in companies conducting research with commercialization objectives. This runs through the Semiconductor Ecosystem Investment Fund under the reestablished National Semiconductor Technology Center — now administered directly by NIST, following the defunding of Natcast in August 2025.

The critical mechanic: applicants no longer choose their path. CRDO makes that determination from the white paper. You write one document; the office decides whether you are an R&D grantee or an investment target. That elevates the white paper from a screening formality into the single highest-leverage document in the process.

The other feature worth internalizing before you write anything: applicants on either path "may be required to issue — and should anticipate issuing — equity, warrants, licenses to intellectual property, royalties or revenue sharing" to secure a federal return on investment. This is not a grant in the traditional sense. It is closer to sovereign venture capital with a federal mission overlay, and a company that has not pre-cleared that structure with its board and existing investors will discover the problem at the worst possible moment.

Who can compete, and the floor that eliminates most applicants

Eligibility is broad in category and narrow in practice. For-profit and nonprofit organizations, accredited universities, FFRDCs, and federal entities may all apply. All must be domestic entities — organized under U.S. law with a principal place of business in the United States. Individuals and sole proprietors are excluded outright.

The real filter is the money. Project budgets must be at least $10 million, regardless of path. CRDO's guidance is that budgets "need to reflect the actual needs of the proposed project," which is a polite way of saying that padding a $3 million research program to $10 million will be visible and fatal.

Cost share is not universally mandated, but CRDO reserves the right to fund only part of a project where the applicant can demonstrate resources to complete the rest — a provision that quietly advantages well-capitalized applicants and consortia.

Technical scope runs to microelectronics work with a nexus to artificial intelligence, quantum technology, biotechnology, biomanufacturing, commercialization of innovation, or standards development. That list is broader than "chips" in the narrow sense, and the AI and biomanufacturing intersections in particular have absorbed applicants who would not have described themselves as semiconductor companies two years ago.

Multiple white paper submissions are permitted, provided each represents a technically distinct project. Everything moves through Grants.gov. Pre-negotiation packages are invitation-only — an uninvited package is not reviewed, full stop.

Why a two-month pause matters more than it sounds

The instinct with a rolling BAA is to treat any pause as a scheduling inconvenience. Three reasons it is more than that here.

The queue effect. Every applicant who was planning to submit in late September or October now submits in November alongside everyone else. Rolling programs distribute review load precisely because submissions arrive continuously; a pause converts eight weeks of smooth arrivals into a spike. Reviewers facing a stacked queue apply screening criteria harder and faster. A white paper landing in the first week after reopening competes against a compressed field, and marginal submissions fare worse in a crowd than they do alone.

The invitation freeze. The notice explicitly covers "subsequent invitations." If CRDO invited you to submit a pre-negotiation package and your internal timeline had you filing in early October, that timeline is now void. Companies that structured board approvals, partner commitments, or bridge financing around an autumn award decision need to reset those assumptions this week — not in November.

The fiscal-year seam. The pause straddles October 1. A federal program pausing its intake across the start of a fiscal year, during a period when the government is operating under a continuing resolution that runs to December 11, is worth watching. NIST has given a mundane and entirely plausible reason — system upgrades — and there is no evidence of anything else. But applicants should hold the November reopening as an expectation rather than a commitment, and should not build a financing plan that requires the portal to open on a specific date.

What to do with the next four days, and the eight weeks after

If your white paper is 80 percent done, finish it and file by Monday. A rolling BAA with no near-term deadline breeds indefinite polishing. This is the forcing function. A submitted white paper enters review; a perfect unsubmitted one does not. And because white papers can be resubmitted with CRDO feedback, an early imperfect submission buys you something a delayed one cannot: a read on how the office sees your project and which path it would assign you.

If you are further out, use the dark window deliberately. The pause is the best available time to do the work that is hard to do under submission pressure:

• Resolve the equity question internally. Get board and investor alignment on issuing warrants, equity, or IP licenses to the federal government. This kills deals late; kill it early instead.
• Pressure-test the $10 million floor. Build the budget from the technical plan upward. If the honest number is $6 million, find the adjacent scope that makes it genuinely $12 million rather than nominally $10 million.
• Decide which path you want — then write toward it. You do not get to choose, but CRDO chooses from your document. A white paper emphasizing technical risk reduction and milestone-driven research reads as R&D Project. One emphasizing a commercialization thesis, market path, and capital needs reads as Investment Fund. Ambiguity gets you sorted by someone else's default.
• Map the multi-paper strategy. If you have two technically distinct programs, prepare both for November rather than sequencing them across six months.

Watch for changes at reopening. Rolling BAAs get amended during pauses — that is frequently when agencies fold in revisions they have been accumulating. The April 2026 amendment materially restructured the program once already. Re-read the BAA the day the portal reopens rather than assuming the version you drafted against still governs.

The CHIPS R&D Office has committed roughly $874 million in letters of intent to seven companies for compute supply chain R&D this year alone, and the BAA remains open through 2029. This is a long program with a short interruption. But it is an interruption with a hard edge on Monday — and the applicants who treat the next four days as a deadline will be in review while everyone else is still waiting for a portal.

For teams mapping which federal R&D instruments actually fit their technology and capital structure — and what a competitive submission looks like in each — Granted can help you get from a technical concept to a reviewer-ready narrative before the window shifts again.